Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks ...

Sonnet to merge with crypto-backed firm, forming Hyperliquid Strategies with $888 million in assets, plus HYPE blockchain ...

Sonnet BioTherapeutics enters into an agreement to transform into the largest U.S.-based publicly listed company to hold HYPE.

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

CSL shares have faced several headwinds over the past year. Here's what we can expect next from the biotech business.

BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

Saldanha said he hasn’t yet fully figured out how to deploy much of the proceeds of the licensing deal, but added that he ...

The price band has been set at Rs 540 to Rs 570 per share. Investors can apply for a lot of 26 shares and in multiples of ...